MedinCell S.A. MEDCL.PA · Stock Open MedinCell S.A. in new tab
MedinCell S.A. Analysis (MEDCL.PA)
Is MedinCell S.A. a good investment? MedinCell S.A. (MEDCL.PA) is currently trading at 23.18 EUR. Market analysts have a consensus price target of 34.51 EUR. This suggests a potential upside from current levels.
Earnings Schedule: MedinCell S.A. is expected to release its next earnings report on Dec. 8, 2026. The market consensus estimate for Forward EPS is 0.42.
Investor FAQ
Does MedinCell S.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is MedinCell S.A.?
MedinCell S.A. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Dec. 8, 2026. The company currently has a trailing EPS of -0.94.
Company Profile
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
Community Discussion